EMAT stock jumps again premarket as Clear Street starts coverage with $30 target and ownership filing hits

EMAT stock jumps again premarket as Clear Street starts coverage with $30 target and ownership filing hits

February 19, 2026

NEW YORK, Feb 19, 2026, 08:54 AM EST — Premarket

Evolution Metals & Technologies Corp jumped 11.9% to $14.68 ahead of Thursday’s open, building on yesterday’s 27.6% surge that closed the stock at $13.12. Around 41,270 shares changed hands before the bell as of 8:41 a.m. ET.

Traders zeroed in on the newly public critical-minerals firm after a fresh analyst initiation. Tim Moore at Clear Street kicked off coverage with a Buy and a $30 target, Benzinga noted.

Why it matters now: EMAT is still getting its bearings as a newly public stock, and it’s reacting to a narrow set of drivers. As analysts begin issuing initial research and setting some benchmarks, even modest upticks in demand are enough to jolt the shares ahead of the open.

Clear Street is banking on projections that stretch out years and a massive expansion plan, per an Investing.com note on the new coverage. According to the report, analysts based their valuation on an EBITDA target for 2028, working off the assumption that the company will go out and secure fresh capital—dilution possible—to back a $2.5 billion U.S. investment push. U.S. revenue could start flowing in late Q3 2027, provided the funding comes through.

A Schedule 13D filed late Wednesday revealed Executive Chairman David Wilcox and The Zeus Trust together control 416,436,066 common shares—roughly 70.18% of the company’s 593,349,852 shares outstanding. According to the filing, their stake remains locked up until the third anniversary of the business-combination closing. The document also details registration rights that would enable resale once certain conditions are satisfied.

Evolution Metals went public via a merger with a special purpose acquisition company in early January. Wilcox called the transaction “a credible alternative…to China’s dominance in rare earth magnets and critical materials.” CEO Frank Moon said their main goal is to “replicate and scale” these capabilities inside the U.S. GlobeNewswire

But there’s a flip side here. The stock’s big swings can snap back just as fast if sentiment outruns the short-term reality. Investors are still waiting for details on funding, execution, and how much new equity will be required to expand U.S. capacity.

Later Thursday brings the next driver: the company plans an investor and analyst webinar from 10 a.m. to 11 a.m. ET, featuring its management’s presentation and a Q&A session. According to the company, it develops rare earth and battery-related materials out of both the U.S. and South Korea, with ambitions to expand stateside through a new industrial campus. That campus would include a hydrometallurgical facility—a water-based chemical process for metal separation.

Stock Market Today

  • Bell Potter Sees Potential 100%+ Gain in Imugene ASX Healthcare Stock
    May 28, 2026, 7:13 PM EDT. Imugene Ltd (ASX: IMU) shares surged after Bell Potter highlighted progress in its Phase 1b trial targeting rare Non-Hodgkin's Lymphoma (NHL). The trial tests azer-cel combined with BTKi drugs, aiming to improve treatment for patients resistant to previous therapies. Bell Potter is optimistic, citing high response rates in related studies and the advantage of the off-the-shelf availability of azer-cel. The broker expects rapid enrolment and early data within weeks, reaffirming a speculative buy rating with a 25 cent price target, over double the current share price. Imugene addresses a critical unmet medical need, positioning it as a notable ASX healthcare stock with significant upside potential.